安罗替尼联合DC-CIK细胞免疫治疗老年非小细胞肺癌的疗效分析

Efficacy Analysis of Antirotinib Combined with DC-CIK Cell Immunotherapy for Senile Non-Small Cell Lung Cancer

摘要: 目的：分析老年非小细胞肺癌采取安罗替尼联合DC-CIK细胞免疫治疗的临床疗效。方法：收集2021年1月~2023年1月入院就诊的老年非小细胞肺癌患者80例作为观察对象，采取随机法将其分组，40例患者接受TP化疗方案开展治疗，作为对照组，剩余40例患者在化疗治疗基础之上应用安罗替尼联合DC-CIK细胞免疫治疗，作为研究组，对比两组患者治疗效果之间的差异性。结果：研究组患者治疗之后的糖类抗原125以及肺腺癌转移相关转录因子水平和对照组比较明显下降，对比具有统计学意义(P < 0.05)；研究组患者疾病控制率和对照组比较明显升高，对比具有统计学意义(P < 0.05)；两组出现不良反应例数对比不具有统计学意义(P > 0.05)。结论：临床中为老年非小细胞肺癌患者提供化疗治疗基础之上加用安罗替尼联合DC-CIK细胞免疫治疗，能够有效提高疾病的控制率，不会增加不良反应出现风险，治疗效果确切。

Abstract: Objective: To analyze the clinical efficacy of antirotinib combined with DC-CIK cell immunotherapy in elderly patients with non-small cell lung cancer (NSCLC). Methods: A total of 80 elderly patients with non-small cell lung cancer (NSCLC) admitted from January 2021 to January 2023 were collected as observation objects and divided into groups by random method. 40 patients received TP chemo-therapy and the remaining 40 patients were treated with anrotinib combined with DC-CIK cell im-munotherapy on the basis of chemotherapy. As a study group, the differences in treatment effects between the two groups were compared. Results: The levels of carbohydrate antigen 125 and lung adenocarcinoma metastasis-related transcription factors in the study group were significantly low-er than those in the control group after treatment, with statistical significance (P < 0.05). The dis-ease control rate of the study group was significantly higher than that of the control group, with sta-tistical significance (P < 0.05). There was no statistical significance in the number of adverse reac-tions between the two groups (P > 0.05). Conclusion: The combination of antirotinib and DC-CIK cell immunotherapy on the basis of chemotherapy for elderly patients with non-small cell lung cancer can effectively improve the disease control rate without increasing the risk of adverse reactions, and the therapeutic effect is accurate.